SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Seattle Genetics (SGEN)

SGEN RSS Feed
Add SGEN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 11/9/2016 2:55:55 PM - Followers: 22 - Board type: Free - Posts Today: 0
http://www.seattlegenetics.com

http://finance.yahoo.com/q/ks?s=SGEN

http://www.form4oracle.com/company?cik=0001060736&ticker=sgen

Seattle Genetics, Inc. operates as a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer, including lymphoma, multiple myeloma, leukemia, and solid tumors. The company has a worldwide collaboration agreement with Genentech, Inc. to develop and commercialize SGN-40, a humanized monoclonal antibody that is in phase I and phase II clinical development for patients with diffuse large B-cell lymphoma and multiple myeloma. It also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35, and SGN-30. The company's SGN-33 is in a phase IIb clinical trial for the patients with acute myeloid leukemia or myelodysplastic syndromes; and SGN-30 and SGN-35 are in phase II clinical trails for the treatment of CD30-positive hematologic malignancies, such as Hodgkin's disease and anaplastic large cell lymphoma. In addition, it developed proprietary antibody-drug conjugate (ADC) technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. The company's product candidates also include SGN-70, a humanized anti-CD70 monoclonal antibody with potent effector function and intrinsic cell-killing ability; and SGN-75, which consists of an anti-CD70 monoclonal antibody linked to an auristatin derivative using its proprietary ADC technology. Seattle Genetics has license agreements with Bayer, CuraGen, Progenics, MedImmune, and PDL BioPharma to use its proprietary ADC technology with their monoclonal antibodies; and an ADC co-development agreement with Agensys and Celera Genomics. The company was founded in 1997 and is headquartered in Bothell, Washington
.





  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SGEN
Current Price
Volume:
Bid Ask Day's Range
SureTrader
SGEN News: Takeda & Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Ex... 12/03/2016 05:00:00 PM
SGEN News: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in F... 12/03/2016 03:00:00 PM
SGEN News: Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-ce... 12/03/2016 01:00:00 PM
SGEN News: Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting 11/29/2016 08:00:00 AM
SGEN News: Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis Fungoides & Pr... 11/10/2016 08:00:00 AM
PostSubject
#217   Up 15% on Ph3 trial enlistment filled. shub 11/09/16 02:55:55 PM
#216   SGEN bullish 55.18 stocktrademan 10/08/16 01:20:59 PM
#215   SGEN H D W TREND1 08/10/16 03:04:30 PM
#214   SGEN DAY TREND1 07/29/16 03:38:02 PM
#213   Delving Into Seattle Genetics’s Upcoming Readout http://marketexclusive.com/de trendmkr 07/28/16 02:48:23 PM
#212   Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Mitshu35 07/25/16 09:48:02 AM
#211   *****Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that TREND1 07/16/16 03:28:06 PM
#210   Short % of Float = 24.5% TREND1 07/16/16 01:15:12 PM
#209   ***** SGEN DAY TREND1 07/16/16 01:06:50 PM
#208   Inst % Owned = 99% TREND1 07/16/16 12:59:13 PM
#207   FLOAT=61 MILLION TREND1 07/16/16 12:58:20 PM
#206   EPS=-.93 TREND1 07/16/16 12:57:17 PM
#205   *****AML Therapies: Seattle Genetics Vs. GlycoMimetics TREND1 07/16/16 11:28:41 AM
#204   $SGEN recent news/filings stocktrademan 06/02/15 02:59:40 PM
#203   $SGEN Intraday Elliott Wave Analysis 03/16/15 (VIDEO) FutureMeDead 03/16/15 11:58:35 AM
#202   Burning down the house against a weak tape. chef911 03/10/15 01:49:59 PM
#201   Seattle Genetics: Continued Quality And Breadth Of Data maytepper 12/09/14 01:30:55 PM
#200   Wow, that's very interesting. Thank you for providing InvestmentFan 11/07/14 02:34:42 PM
#199   https://ash.confex.com/ash/2014/webprogram/Paper67048.html north40000 11/06/14 10:07:05 AM
#198   Good data, dumb CC: DewDiligence 09/29/14 07:23:40 PM
#197   http://ih.advfn.com/p.php?pid=nmona&article=63542299 >>> Additional collaborati north40000 09/10/14 01:59:39 PM
#196   Seattle Genetics: Recent Macro Weakness Has Created A maytepper 08/01/14 03:18:46 PM
#195   Falling Knife? On 06/04/14, FELIX BAKER, reported a net RVL 06/04/14 07:36:02 PM
#194   Thankfully, I did. RVL RVL 06/03/14 07:40:39 PM
#193   Thankfully, I did. RVL 06/03/14 07:40:05 PM
#191   Who is going to grab the falling knife cdaniel394 03/28/14 05:53:01 PM
#190   I'm interested in #SGEN KICK1 03/19/14 07:42:46 PM
#189   http://www.insidermonkey.com/blog/baker-bros-strengthens-position-in-seattle-gen buccaneer1961 12/17/13 08:36:24 PM
#188   8:32AM Seattle Genetics highlights ADCETRIS Phase 2 Clinical surf1944 12/10/13 10:36:26 AM
#187   11:32AM Seattle Genetics highlights data from broad ADCETRIS surf1944 12/09/13 02:14:58 PM
#186   We're going to see a big run any pete7 12/06/13 12:58:13 PM
#185   9:02AM Seattle Genetics to present clinical data from surf1944 11/11/13 11:09:46 AM
#184   9:02AM Seattle Genetics highlights ADCETRIS (Brentuximab Vedotin) clinical surf1944 10/11/13 11:21:25 AM
#183   William-Blair Conference updates ECole 07/12/13 10:45:50 AM
#182   9:05AM Seattle Genetics and Agensys, an Affiliate of surf1944 06/27/13 02:10:18 PM
#181   Seattle Genetics enters into new antibody-drug conjugate collaboration mlkrborn 06/25/13 11:40:10 AM
#180   1:50AM Seattle Genetics highlights ADCETRIS Frontline HL and surf1944 06/03/13 09:46:03 AM
#179   Seattle Genetics SGEN RBC Capital Mkts Outperform $32 » $40 surf1944 04/22/13 10:12:18 AM
#178   Seattle Genetics to Present at Upcoming Investor Conferences surf1944 02/27/13 10:37:51 AM
#177   10:01AM Seattle Genetics highlights ADCETRIS (brentuximab vedotin) data surf1944 12/10/12 01:13:42 PM
#176   9:01AM Seattle Genetics expands antibody-drug conjugate collaboration with surf1944 10/23/12 10:22:17 AM
#175   ADC Commercial Leader’s Day 23rd October, 2012 WID 10/19/12 03:45:12 PM
#174   Third Annual Meeting World ADC 2012 WID 10/19/12 01:46:42 PM
#173   9:03AM Seattle Genetics achieves milestones as Roche's (RHHBY) surf1944 10/09/12 12:06:51 PM
#172   5:45AM Seattle Genetics and Takeda (TKPYY) unit Millennium surf1944 10/01/12 08:59:03 AM
#171   Seattle Genetics Announces Initiation of a Phase Ib surf1944 09/03/12 12:13:18 AM
#170   >>> Rethinking Antibody-Drug Conjugates gfp927z 06/19/12 07:22:38 AM
#169   7:00AM Seattle Genetics highlights updated survival data from surf1944 06/14/12 08:36:33 AM
#168   That was a great interview. The CEO RookieInvestor1 06/06/12 12:58:33 PM
#167   Cramer just had the CEO on, pluggin' SGEN~ Quik18holes 06/05/12 06:54:01 PM
PostSubject